Axogen, Inc. (AXGN) News
Follow Axogen, Inc. (AXGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Axogen Price Target Raised to $53.00/Share From $48.00 by Raymond James
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:40 PM UTC
H
Axogen to acquire BioCircuit for $200 million in cash
Axogen Inc. agreed to acquire BioCircuit Technologies Inc. for $200 million in cash, integrating NerveTape into its surgical solutions. To finance the purchase, it launched an underwritten public offering of 4.91 million
MNA | Sep 10, 2026, 04:31 PM UTC
L
Axogen $200 million acquisition adds NerveTape to portfolio
Axogen, Inc. is acquiring BioCircuit for $200 million, bringing NerveTape—a high-growth, FDA-approved nerve repair device—into the portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027.
EARNINGS | Sep 10, 2026, 01:18 PM UTC
L
AXGN to buy BioCircuit for $200 million cash acquisition
AXGN will pay $200 million in cash to acquire BioCircuit, adding NerveTape and an FDA-approved suture-less nerve repair device to its portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027.
EARNINGS | Sep 10, 2026, 12:52 PM UTC
L
AXGN to buy an FDA-cleared sutureless nerve repair for $200M cash
Axogen said it will acquire a differentiated, FDA-cleared sutureless nerve repair device. The $200M cash deal is expected to be accretive to revenue and margins in Year 1, with closing expected in Q4 2026.
EARNINGS | Sep 10, 2026, 11:27 AM UTC
H
Axogen to buy BioCircuit Technologies for $200M in cash
Axogen, NASDAQ:AXGN, has agreed to acquire privately held medical-device company BioCircuit Technologies for $200M in cash. The company plans to fund the purchase price with net proceeds from a concurrent public offer.
MNA | Sep 10, 2026, 11:11 AM UTC
L
Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN
Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN
EQUITY | Sep 10, 2026, 10:16 AM UTC
L
Axogen enters definitive agreement to acquire BioCircuit Technologies
Axogen Enters Into Definitive Agreement To Acquire BioCircuit Technologies >AXGN
MNA | Sep 10, 2026, 10:04 AM UTC
M
Axogen prices $208.7 million public common stock offering
EQUITY | Sep 10, 2026, 10:01 AM UTC
L
Axogen management to meet investors at Morgan Stanley healthcare conference
Axogen said management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
Axogen to participate in Morgan Stanley Global Healthcare conference
Axogen, Inc. will participate in the 24th Annual Morgan Stanley Global Healthcare Conference.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
AXGN Axogen RESULTS: Q2, Q2 REV $69.7M vs. EST $67.1M, Q2 gross margin 72.7%, Q2 ADJ EBITDA $8.4M, Q2 ADJ Net Income $7.3M, Q2 Net Income $
AXGN Axogen RESULTS: Q2, Q2 REV $69.7M vs. EST $67.1M, Q2 gross margin 72.7%, Q2 ADJ EBITDA $8.4M, Q2 ADJ Net Income $7.3M, Q2 Net Income $-1.5M, Q2 ADJ EPS $0.12 vs. EST $0.12, Axogen Earnings Notes:, Outlook FY REV $27
EARNINGS | Jul 29, 2026, 11:07 AM UTC
L
AXGN - Axogen, Inc. Reports Second Quarter 2026 Financial Results
AXGN - Axogen, Inc. Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 11:05 AM UTC
L
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - CAR, ASH, TLRY, PDM, BRSP, TRTX, PDS, TTAM, NO
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - CAR, ASH, TLRY, PDM, BRSP, TRTX, PDS, TTAM, NOV, MEOH, AAT, SW, AXGN
EARNINGS | Jul 28, 2026, 04:09 PM UTC
L
STIM AXGN Neuronetics appoints nir naor Chief Financial Officer; announces additional management changes
STIM AXGN Neuronetics appoints nir naor Chief Financial Officer; announces additional management changes
EQUITY | Jul 20, 2026, 08:05 PM UTC